Department of Medicine, Pak Emirates Military Hospital, Rawalpindi, Pakistan.
Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan.
J Coll Physicians Surg Pak. 2024 Sep;34(9):1061-1065. doi: 10.29271/jcpsp.2024.09.1061.
To compare oral pregabalin with oral sertraline for treatment of uraemic pruritus.
Randomised controlled trial. Place and Duration of the Study: Department of Nephrology, Pak Emirates Military Hospital Rawalpindi, Pakistan, from October 2023 to January 2024.
Patients with end-stage renal disease having pruritus for at least 6 weeks were included. Exclusion criteria comprised other dermatological or systemic diseases associated with pruritus, mental health issues, thrice-a-week haemodialysis schedule, and use of other treatments for uraemic pruritus. They were randomised to receive either pregabalin 75mg daily or sertraline 50mg daily for six weeks using computer-generated sequences. The Urdu version of the 5-D Itch scale was used to document the severity of pruritus at the baseline and at the end of therapy. Side effects to the treatment were also monitored.
There were 8 (16.67%) females and 40 (83.33%) males, with a mean age of 52.19 ± 12.19 years. The baseline 5-D Itch scale scores were equal in both groups. Mean improvement in 5-D Itch scale scores was 3.75 ± 1.26 and 2.08 ± 1.18 with pregabalin and sertraline, respectively (p <0.001). Side effects were reported by 2 (8.33%) patients on pregabalin and none using sertraline (p = 0.489).
Pregabalin was found to be more effective than sertraline in treating uraemic pruritus, though with a statistically insignificant trend towards a higher frequency of side effects.
Chronic renal failure, Pruritus, Renal dialysis, Selective serotonin reuptake inhibitors, Uraemia.
比较口服普瑞巴林与口服舍曲林治疗尿毒症瘙痒。
随机对照试验。
巴基斯坦拉瓦尔品第 Pak Emirates Military 医院肾病科，2023 年 10 月至 2024 年 1 月。
纳入至少患有瘙痒 6 周的终末期肾病患者。排除标准包括其他与瘙痒相关的皮肤病或系统性疾病、精神健康问题、每周三次血液透析方案以及使用其他尿毒症瘙痒治疗方法。他们被随机分配每天接受普瑞巴林 75mg 或舍曲林 50mg 治疗，为期六周，使用计算机生成的序列。使用 5-D 瘙痒量表的乌尔都语版本记录基线和治疗结束时瘙痒的严重程度。还监测了治疗的副作用。
女性 8 例（16.67%），男性 40 例（83.33%），平均年龄 52.19 ± 12.19 岁。两组基线 5-D 瘙痒量表评分相等。普瑞巴林和舍曲林的 5-D 瘙痒量表评分平均改善分别为 3.75 ± 1.26 和 2.08 ± 1.18（p <0.001）。普瑞巴林组有 2 例（8.33%）患者报告有副作用，舍曲林组无副作用（p = 0.489）。
普瑞巴林治疗尿毒症瘙痒的效果优于舍曲林，但副作用发生率略高，但无统计学意义。
慢性肾衰竭、瘙痒、肾透析、选择性 5-羟色胺再摄取抑制剂、尿毒症。
